Spots Global Cancer Trial Database for Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma
Official Title: A Phase I Open-label Study of the Safety and Immunogenicity of Escalating Doses of Lipovaxin-MM, a Novel Melanoma Immunotherapeutic, in Patients With Metastatic Melanoma
Study ID: NCT01052142
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body's ability to destroy cancer cells in patients with metastatic melanoma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Pain & Anaesthesia Research Clinic, Adelaide, South Australia, Australia
Contact Details
Name: Michael Brown, MBBS FRACP FRCPA
Affiliation: Royal Adelaide Hospital Cancer Centre
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
